| Document |
Document Title |
|
WO/2023/000135A1 |
Provided are new process and intermediates for preparing onapristone.
|
|
WO/2023/288123A1 |
The present application relates to methods and novel intermediates useful in the preparation of a compound of formula 100 (Compound 100).
|
|
WO/2023/281388A1 |
The subject matter of the invention is an imidazolium salt, being a derivative of lithocholic acid, with a structural formula (I), wherein X is selected from the group comprising: I, Br, Cl, and R is selected from the group comprising no...
|
|
WO/2023/280313A1 |
Disclosed is a method for purifying ursodeoxycholic acid (UDCA), comprising the following steps: step A sets forth the preparation of 4-dimethylpyridine ammonium salt of UDCA; and step B sets forth the hydrolysis of the 4-dimethylpyridin...
|
|
WO/2022/272103A1 |
25HC3S choline and crystalline 25HC3S choline are described herein. Pharmaceutical formulations of 25HC3S choline such as with crystalline 25HC3S choline and methods of treating or preventing disease with same such as hypercholesterolemi...
|
|
WO/2022/255845A1 |
The present invention relates to a compound having therapeutic activity for total inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. An ergostenol or cholestenol derivative compound according to the present inven...
|
|
WO/2022/238572A1 |
The invention relates to a synthesis of cholesterol; a ring opening step of the compound of formula (I) and subsequent activation and reduction step yielding cholesterol. The inventions relates also to intermediates achieved during said ...
|
|
WO/2022/232945A1 |
Immunogen enhancers for admixture with an antigen of interest are described herein. The enhancers generally comprise a steroid acid and/or a steroid acid-peptide conjugate in an amount sufficient to improve or modify the adaptive immune ...
|
|
WO/2022/228080A1 |
Disclosed is a chemical synthesis method for 7-ketone-based cholic acid (3α-hydroxy-7-ketone-5β-cholesterol-24-acid), which belongs to the field of organic chemical synthesis. A plant-derived compound 21-hydroxy-20-methylpregna-4-ene-3...
|
|
WO/2022/225035A1 |
The purpose of the present invention is to provide a bile acid derivative having an antiviral effect on the hepatitis B virus. Specifically, provided is a pharmaceutical composition for preventing hepatitis B virus (HBV) infection or tre...
|
|
WO/2022/213805A1 |
Disclosed in the present invention is a method for synthesizing cholesterol by using BA as a raw material. A plant-derived raw material 21‑hydroxy‑20‑methylpregn‑4‑en‑3‑one, also known as bisnoralcohol or BA, is used as a r...
|
|
WO/2022/213480A1 |
A method for synthesizing cholesterol by using BA as a raw material: a plant source raw material 21-hydroxy-20-methylpregn-4-en-3-one, also known as bisnoralcohol or BA, is used as a raw material, and is synthesized into cholesterol by u...
|
|
WO/2022/190599A1 |
Provided is a radiation sensitive resin composition that can form a resist film having sufficient levels of sensitivity, CDU performance, and development residue-inhibiting properties when next generation technology is used. Also provide...
|
|
WO/2022/185258A1 |
The invention relates to a method of separation and recovery of neutral and lipid components contained in saponifiable mixtures such as lipids and residues of plant and animal origin or saponified such as Tall Oil Soap (TOS), or in their...
|
|
WO/2022/179666A1 |
The invention relates to a molecular assembly (1) having a structure formation composed of amphiphilic molecules (2), characterized in that the amphiphilic molecules (2) are selected from the group containing amphiphilic molecules (2) wh...
|
|
WO/2022/161468A1 |
The invention provides pharmaceutical compositions of berberine ursodeoxycholate (BUDCA) and methods of use thereof for the treatment primary sclerosing cholangitis, and related diseases and conditions.
|
|
WO/2022/155290A1 |
Novel Fusidic Acid (FA) based compounds that have equivalent potency against clinical isolates of Staphylococcus aureus (S. aureus) and Enterococcus faecium (E. faecium) as well as an improved resistance profile in vitro when compared to...
|
|
WO/2022/139630A1 |
The invention relates to the field of chemistry, and more particularly to a method for producing high-purity phytosterols. The present method includes dissolving a concentrate of tallow oil neutral substances in a mixed solvent consistin...
|
|
WO/2022/115710A1 |
7β-hydroxylation systems are provided, as well as methods for producing ?P-hydroxy derivatives of lithocholic acid and 3-keto-lithocholic acid from such systems. Also provided are recombinant organisms useful for the production of such ...
|
|
WO/2022/100722A1 |
A 5,6-epoxy sterol compound intermediate, and a preparation method therefor and an application thereof. The intermediate has a chemical structure represented by formula I, wherein R is selected from -CH 2OCOR 1 or -CH＝CH-CO(O)R 1, and ...
|
|
WO/2022/083809A1 |
The invention relates to brassinosteroid-derived cholestane derivatives, their use in the protection of cell damage, injury and cell death and compositions containing these derivatives. New generation of compounds possess also selective ...
|
|
WO/2022/045354A1 |
The present invention addresses the problem of providing the development of a simpler, more efficient method for producing a phytosterol starting material. The present invention is a method for producing a phytosterol starting material, ...
|
|
WO/2022/040635A1 |
Prodrugs that target the low-density lipoprotein receptor (LDLR) and that comprise acid and/or enzyme cleavable acetal- or oxybenzyloxy-linked carbonate or carbamate bonds are described. Also described are core-shell nanoparticles compri...
|
|
WO/2021/258723A1 |
Disclosed is a method for synthesizing a lithocholic acid, comprising: using 21-hydroxy-20-methylpregn-4-en-3-one (BA) as a raw material, undergoing an oxidizing reaction and a Wittig reaction, then synthesizing the lithocholic acid thro...
|
|
WO/2021/244051A1 |
The present invention provides an 11-O-mogrol oxime ether derivative and a preparation method therefor. The structural formula is as shown in formula (I). The mogrol oxime ether derivative is a product 11-O-mogrol oxime ether derivative ...
|
|
WO/2021/248049A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds for the modulation of Hedgehog signaling.
|
|
WO/2021/235508A1 |
Provided is a pharmaceutical composition for treating and/or preventing fatty liver diseases, in particular, nonalcoholic fatty liver diseases, said pharmaceutical composition having excellent ACC2-selective inhibitory action without acc...
|
|
WO/2021/231646A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a ΤΗΚ...
|
|
WO/2021/231644A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and an SSAO i...
|
|
WO/2021/222534A1 |
The present invention pertains to anti-coronaviral compounds. The disclosure includes a method for preventing and/or treating a coronavirus infection through the inhibition of a cysteine protease in a virus, particularly SARS-COV-2. Also...
|
|
WO/2021/213984A1 |
The present invention relates to a new synthesis of 7- dehydrocholesterol or itsOH-protected forms of the formula I by the reaction of a compound of formula (ll)in the presence of a solvent of formula (III), comprising the step (a) where...
|
|
WO/2021/214685A1 |
The present invention refers to a method for the preparation of a compound of formula (I).
|
|
WO/2021/213518A1 |
The present invention relates to the field of biomedicine, and specifically relates to an "LC3 binding portion-lipid droplet binding portion-conjugate" formed by means of covalently linking a structure capable of binding LC3 and a struct...
|
|
WO/2021/213988A1 |
The present invention relates to the purification of 7-dehydrocholesterol or 25-hydroxy-7-dehydrocholesterol or their OH-protected forms, respectively. It has been found that the process using organic solvent nanofiltration allows an eff...
|
|
WO/2021/200179A1 |
The present invention provides an actinic-ray-sensitive or radiation-sensitive resin composition comprising (A) a resin which increases in polarity by the action of an acid and (B) a compound which generates an acid upon irradiation with...
|
|
WO/2021/194244A1 |
The present invention relates to a novel method for preparing Inotodiol. The method differs in terms of process from existing methods for preparing Inotodiol, and produces a high yield of Inotodiol. Therefore, the method can be useful fo...
|
|
WO/2021/188778A2 |
Provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R 4a, R4b, R5, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R18, R19, R20a, R20b, X, A, Z, q, u, r, s, t, m, and n are de...
|
|
WO/2021/153708A9 |
Provided is a novel growth inhibitor of Helicobacter pylori. This growth inhibitor of Helicobacter pylori comprises, as an active ingredient, stenone and/or a compound having a sterol skeleton other than cholesterol.
|
|
WO/2021/182111A1 |
Provided is a composition for stabilizing proteins. More specifically, the invention provides a compound represented by general formula (I). [In the formula, R represents a saturated or unsaturated hydrocarbon group; X represents a hydro...
|
|
WO/2021/167770A1 |
Disclosed are immune cell-selective small molecule compounds that modulate certain immune cell-specific receptors and enzymes, and methods of their synthesis and use to treat proliferative disorders.
|
|
WO/2021/157665A1 |
The present invention provides a hyaluronic acid derivative into which a steryl group is introduced, wherein the ratio (Mw/Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) of the hyaluronic acid...
|
|
WO/2021/155167A1 |
GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.
|
|
WO/2021/140480A1 |
It is provided a method for the preparation of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-carboxyl
ic acid comprising the step of: d) reacting compound (IV) with methane sulphonyl chloride to get methyl 7α,12α-diacetyloxy-3α-...
|
|
WO/2021/120127A1 |
The present invention relates to the field of pharmaceutical chemistry, and in particular relates to a method for preparing cholesterol, a derivative and an analogue thereof. The cholesterol derivative comprises, but is not limited to, 7...
|
|
WO/2021/121239A1 |
The present invention relates to the field of pharmaceutical chemistry, and specifically to a method for preparing cholesterol, a derivative thereof, and an analog thereof. The derivative of cholesterol comprises, but is not limited to, ...
|
|
WO/2021/116935A1 |
The present invention relates to compounds of formula (I), to pharmaceutical compositions thereof and to their uses, in particular in the treatment and/or prevention of GPBAR1 mediated diseases.
|
|
WO/2021/109791A1 |
A method for synthesizing ursodeoxycholic acid, comprising: taking a plant-derived compound BA as a raw material, and synthesizing ursodeoxycholic acid by the steps of ethylene glycol or neopentyl glycol protection, oxidation, Wittig rea...
|
|
WO/2021/109883A1 |
Provided in the present invention is a method for use in preparing obeticholic acid. Specifically, the present invention prepares the compound as represented by formula (1) by employing a novel intermediate and route. The method is simpl...
|
|
WO/2021/105147A1 |
It is provided a cocrystal of a compound of formula (I) or of a compound formula (II) wherein X and Y are independently selected from -CH2- and -C(CH2)-, provided that al least one of X or Y is -CH2-; R1 is -CHCH3-Zm-Wn-(CH2)o-Tp-S, wher...
|
|
WO/2021/058648A1 |
A process for purification of phytosterols, said process comprising, a. providing a liquid mixture comprising a phytosterol, lower alcohol, wherein the lower alcohol is present in an amount of from 25 to 800% by weight, based on the amou...
|
